世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

インシリコ創薬市場 - 世界の産業規模、シェア、動向、機会、予測、2017-2027コンポーネント別(ソフトウェア、サービス型ソフトウェア、サービス型コンサルタント)、ワークフロー別(探索、前臨床試験、臨床試験)、ソフトウェアタイプ別(分子モデリング&De Novoドラッグデザインソフトウェア、ファーマコフォアモデリングソフトウェア)、技術別(人工知能、グラフィック・プロセッシング・ユニット、その他)、治療領域別(ヒト免疫不全ウイルス(HIV)、感染症、代謝疾患、腫瘍疾患、その他)、エンドユーザー別(バイオテクノロジー・製薬企業、受託研究機関、学術・研究機関、その他)、企業別、地域別


In Silico Drug Discovery Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027Segmented By Component (Software, Software-as-a-Service, Consultancy-as-a-Service), By Workflow (Discovery, Pre-Clinical Tests, Clinical Trials), By Software Type (Molecular Modeling & De Novo Drug Design Software, Pharmacophore Modeling Software), By Technology (Artificial Intelligence, Graphics Processing Unit, Others), By Therapeutic Area (Human Immunodeficiency Virus (HIV), Infectious Diseases, Metabolic Disorders, Oncology Disorders, Others), By End User (Biotechnology & Pharmaceutical Companies, Contract Research Organizations, Academic & Research Organizations, Others), By Company and By Region

世界のインシリコ創薬市場は、予測期間2023-2027年に目覚ましい成長を遂げると予測されている。主な要因としては、様々な疾病の増加、クラウドベースのアプリケーションの利用増加、技術の広範な発展などが挙げら... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
TechSci Research
テックサイリサーチ
2023年8月1日 US$4,900
シングルユーザライセンス
ライセンス・価格情報・注文方法はこちら
117 英語

 

サマリー

世界のインシリコ創薬市場は、予測期間2023-2027年に目覚ましい成長を遂げると予測されている。主な要因としては、様々な疾病の増加、クラウドベースのアプリケーションの利用増加、技術の広範な発展などが挙げられ、これらは市場の成長を抑制している。現在、インシリコ手法は創薬プロセスにおいて不可欠なものとなりつつある。これは主に、コストと時間を大幅に削減しながら新薬の可能性を特定・発見し、医薬品開発全体の軌道に影響を与えるためである。市場の成長を支えるその他の要因としては、広範な研究開発、さまざまな疾患の流行、多数の臨床試験、医療過誤や再入院率の削減に対する重点の高まり、さまざまな投資、企業間の協力関係の増加、創薬データ量の増加などが挙げられます。
クラウドベース・アプリケーションの採用増加
クラウドアプリケーションの利用が増加していることが、インシリコ創薬市場の成長を後押ししている。クラウドコンピューティングにより、製薬研究者は実質的に無限の計算資源を利用できるようになり、コンピューティング環境の拡張や縮小が可能になる。クラウド・コンピューティングは全体的な生産性を向上させるだけでなく、臨床失敗の可能性を最小限に抑える。例えば2020年には、ブリストル大学の研究者がクラウドベースのソリューションを利用して、ADDomerと呼ばれる予防介入の可能性のある物質の構造を解釈することに成功したとされている。
技術の進歩が市場を支える
計算生物学の分野における急速な技術進歩が、in-silico創薬市場の世界的成長を後押ししている。計算技術は、新規医薬化合物の開発に極めて有効である。技術の進歩により、シーケンシングの様々なステップが簡素化され、得られる結果はより迅速で正確なものとなっている。例えば、2021年、ファイザー社とアマゾン・ウェブ・サービス(AWS)は、新薬の研究、製造、臨床試験のための普及方法を近代化する可能性のある新しいクラウドベースの技術開発で協力することを承認した。同様に、2022年には、Insilico Medicineとチューリッヒ大学が、InsilicoのダイナミックAI技術を活用して新たなシスチン症治療法を発見するために協力した。
投資とコラボレーションの増加
様々な疾患の発生が増加する中、創薬開発への多額の投資が市場の成長を後押ししている。例えば、2021年に米国研究製薬工業協会(PhRMA)が発表した報告書によると、バイオ医薬品企業は過去10年間で研究開発に1兆ドル以上を投資しており、このうちPhRMA加盟業界だけで約910億米ドルを投資した2020年は過去最高を記録した。さらに、AIスタートアップ企業が大手研究センターと提携する件数が増えていることも、別の指標を提供する可能性がある。例えば、2017年に開始したGSKとの3,300万ポンドのパートナーシップの一環として、2019年にExscientiaは慢性閉塞性肺疾患の治療をターゲットとしたリード分子を提供した。
市場区分
世界のインシリコ創薬市場は、コンポーネント、ワークフロー、ソフトウェアタイプ、テクノロジー、治療領域、エンドユーザー、企業に区分される。コンポーネントに基づくと、市場はソフトウェア、サービス型ソフトウェア、サービス型コンサルタントに分けられる。ワークフローに基づくと、市場は探索、前臨床試験、臨床試験に分けられる。探索に基づくと、市場はさらに標的同定、標的検証、リード探索に区分される。ソフトウェアの種類に基づくと、市場は分子モデリング&de novoドラッグデザインソフトウェアとファーマコフォアモデリングソフトウェアに区分される。技術別では、人工知能、グラフィック・プロセッシング・ユニット、その他に区分される。治療分野別では、市場はヒト免疫不全ウイルス(HIV)、感染症、代謝疾患、腫瘍疾患、その他に区分される。エンドユーザー別では、バイオテクノロジー・製薬企業、受託研究機関、学術・研究機関、その他に区分される。国別では、米国は広範な技術開発が行われているため、予測期間中に有利な市場になると予想される。
市場プレイヤー
アラジェン・ライフサイエンス社(Aragen Life Sciences Pvt.(GVK Biosciences Pvt. Ltd.)、Curia Global, Inc. (Albany Molecular Research Inc.)、Charles River Laboratories International, Inc.、Chemical Computing Group ULC.(CCG)、Collaborative Drug Discovery Inc.(CDD)、e-therapeutics plc.、Dassault Systèmes SE、Insilico Medicine, Inc.、Numerate, Inc.、Schrödinger, Inc.などが市場で事業を展開している大手企業である。
レポートの範囲
本レポートでは、世界のインシリコ創薬市場を、業界動向に加えて以下のカテゴリーに分類し、その詳細も記載しています:
- インシリコ創薬市場、コンポーネント別
ソフトウェア
o サービス型ソフトウェア
o コンサルタントサービス
- インシリコ創薬市場:ワークフロー別
o 発見
 ターゲット同定
 ターゲットバリデーション
 リード探索
o 臨床前試験
臨床試験
- インシリコ創薬市場、ソフトウェアタイプ別:
o 分子モデリング&デノボドラッグデザインソフトウェア
o ファーマコフォアモデリングソフトウェア
- インシリコ創薬市場:技術別
o 人工知能
o グラフィック・プロセッシング・ユニット
o その他
- インシリコ創薬市場:治療領域別
o ヒト免疫不全ウイルス(HIV)
o 感染症
o 代謝疾患
癌疾患
o その他
- インシリコ創薬市場、エンドユーザー別
o バイオテクノロジーおよび製薬会社
o 受託研究機関
o 学術・研究機関
その他
- インシリコ創薬市場:地域別
o 北米
o 米国
カナダ
o メキシコ
o アジア太平洋
o 中国
o インド
日本
o オーストラリア
o 韓国
o ヨーロッパ & CIS
o ドイツ
o フランス
o イギリス
o スペイン
o イタリア
o 南アメリカ
o ブラジル
o アルゼンチン
o コロンビア
o 中東・アフリカ
o 南アフリカ
o サウジアラビア
o アラブ首長国連邦
競合状況
企業プロフィール:世界のインシリコ創薬市場における主要企業の詳細分析
利用可能なカスタマイズ:
TechSci Research社は、与えられた市場データをもとに、企業固有のニーズに応じたカスタマイズを提供しています。本レポートでは以下のカスタマイズが可能です:
企業情報
- 追加市場参入企業(最大5社)の詳細分析とプロファイリング

ページTOPに戻る


目次

1. Product Overview
2. Research Methodology
3. Executive Summary
4. Impact of COVID-19 on Global In Silico Drug Discovery Market
5. Voice of Customer
6. Global In Silico Drug Discovery Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Component (Software, Software-as-a-Service, Consultancy-as-a-Service)
6.2.2. By Workflow (Discovery, Pre-Clinical Tests, Clinical Trials)
6.2.2.1. By Discovery (Target Identification, Target Validation, Lead Discovery)
6.2.3. By Software Type (Molecular Modeling & De Novo Drug Design Software, Pharmacophore Modeling Software)
6.2.4. By Technology (Artificial Intelligence, Graphics Processing Unit, Others)
6.2.5. By Therapeutic Area (Human Immunodeficiency Virus (HIV), Infectious Diseases, Metabolic Disorders, Oncology Disorders, Others)
6.2.6. By End User (Biotechnology & Pharmaceutical Companies, Contract Research Organizations, Academic & Research Organizations, Others)
6.2.7. By Company (2021)
6.2.8. By Region
6.3. Market Map
7. North America In Silico Drug Discovery Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Component (Software, Software-as-a-Service, Consultancy-as-a-Service)
7.2.2. By Workflow (Discovery, Pre-Clinical Tests, Clinical Trials)
7.2.2.1. By Discovery (Target Identification, Target Validation, Lead Discovery)
7.2.3. By Software Type (Molecular Modeling & De Novo Drug Design Software, Pharmacophore Modeling Software)
7.2.4. By Technology (Artificial Intelligence, Graphics Processing Unit, Others)
7.2.5. By Therapeutic Area (Human Immunodeficiency Virus (HIV), Infectious Diseases, Metabolic Disorders, Oncology Disorders, Others)
7.2.6. By End User (Biotechnology & Pharmaceutical Companies, Contract Research Organizations, Academic & Research Organizations, Others)
7.2.7. By Country
7.3. North America: Country Analysis
7.3.1. United States In Silico Drug Discovery Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Component
7.3.1.2.2. By Workflow
7.3.1.2.3. By Software Type
7.3.1.2.4. By Technology
7.3.1.2.5. By Therapeutic Area
7.3.1.2.6. By End User
7.3.2. Canada In Silico Drug Discovery Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Component
7.3.2.2.2. By Workflow
7.3.2.2.3. By Software Type
7.3.2.2.4. By Technology
7.3.2.2.5. By Therapeutic Area
7.3.2.2.6. By End User
7.3.3. Mexico In Silico Drug Discovery Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Component
7.3.3.2.2. By Workflow
7.3.3.2.3. By Software Type
7.3.3.2.4. By Technology
7.3.3.2.5. By Therapeutic Area
7.3.3.2.6. By End User
8. Europe In Silico Drug Discovery Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Component (Software, Software-as-a-Service, Consultancy-as-a-Service)
8.2.2. By Workflow (Discovery, Pre-Clinical Tests, Clinical Trials)
8.2.2.1. By Discovery (Target Identification, Target Validation, Lead Discovery)
8.2.3. By Software Type (Molecular Modeling & De Novo Drug Design Software, Pharmacophore Modeling Software)
8.2.4. By Technology (Artificial Intelligence, Graphics Processing Unit, Others)
8.2.5. By Therapeutic Area (Human Immunodeficiency Virus (HIV), Infectious Diseases, Metabolic Disorders, Oncology Disorders, Others)
8.2.6. By End User (Biotechnology & Pharmaceutical Companies, Contract Research Organizations, Academic & Research Organizations, Others)
8.2.7. By Country
8.3. Europe: Country Analysis
8.3.1. France In Silico Drug Discovery Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Component
8.3.1.2.2. By Workflow
8.3.1.2.3. By Software Type
8.3.1.2.4. By Technology
8.3.1.2.5. By Therapeutic Area
8.3.1.2.6. By End User
8.3.2. Germany In Silico Drug Discovery Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Component
8.3.2.2.2. By Workflow
8.3.2.2.3. By Software Type
8.3.2.2.4. By Technology
8.3.2.2.5. By Therapeutic Area
8.3.2.2.6. By End User
8.3.3. United Kingdom In Silico Drug Discovery Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Component
8.3.3.2.2. By Workflow
8.3.3.2.3. By Software Type
8.3.3.2.4. By Technology
8.3.3.2.5. By Therapeutic Area
8.3.3.2.6. By End User
8.3.4. Italy In Silico Drug Discovery Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Component
8.3.4.2.2. By Workflow
8.3.4.2.3. By Software Type
8.3.4.2.4. By Technology
8.3.4.2.5. By Therapeutic Area
8.3.4.2.6. By End User
8.3.5. Spain In Silico Drug Discovery Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Component
8.3.5.2.2. By Workflow
8.3.5.2.3. By Software Type
8.3.5.2.4. By Technology
8.3.5.2.5. By Therapeutic Area
8.3.5.2.6. By End User
9. Asia-Pacific In Silico Drug Discovery Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Component (Software, Software-as-a-Service, Consultancy-as-a-Service)
9.2.2. By Workflow (Discovery, Pre-Clinical Tests, Clinical Trials)
9.2.2.1. By Discovery (Target Identification, Target Validation, Lead Discovery)
9.2.3. By Software Type (Molecular Modeling & De Novo Drug Design Software, Pharmacophore Modeling Software)
9.2.4. By Technology (Artificial Intelligence, Graphics Processing Unit, Others)
9.2.5. By Therapeutic Area (Human Immunodeficiency Virus (HIV), Infectious Diseases, Metabolic Disorders, Oncology Disorders, Others)
9.2.6. By End User (Biotechnology & Pharmaceutical Companies, Contract Research Organizations, Academic & Research Organizations, Others)
9.2.7. By Country
9.3. Asia-Pacific: Country Analysis
9.3.1. China In Silico Drug Discovery Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Component
9.3.1.2.2. By Workflow
9.3.1.2.3. By Software Type
9.3.1.2.4. By Technology
9.3.1.2.5. By Therapeutic Area
9.3.1.2.6. By End User
9.3.2. India In Silico Drug Discovery Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Component
9.3.2.2.2. By Workflow
9.3.2.2.3. By Software Type
9.3.2.2.4. By Technology
9.3.2.2.5. By Therapeutic Area
9.3.2.2.6. By End User
9.3.3. Japan In Silico Drug Discovery Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Component
9.3.3.2.2. By Workflow
9.3.3.2.3. By Software Type
9.3.3.2.4. By Technology
9.3.3.2.5. By Therapeutic Area
9.3.3.2.6. By End User
9.3.4. South Korea In Silico Drug Discovery Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Component
9.3.4.2.2. By Workflow
9.3.4.2.3. By Software Type
9.3.4.2.4. By Technology
9.3.4.2.5. By Therapeutic Area
9.3.4.2.6. By End User
9.3.5. Australia In Silico Drug Discovery Market Outlook
9.3.5.1. Market Size & Forecast
9.3.5.1.1. By Value
9.3.5.2. Market Share & Forecast
9.3.5.2.1. By Component
9.3.5.2.2. By Workflow
9.3.5.2.3. By Software Type
9.3.5.2.4. By Technology
9.3.5.2.5. By Therapeutic Area
9.3.5.2.6. By End User
10. South America In Silico Drug Discovery Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Component (Software, Software-as-a-Service, Consultancy-as-a-Service)
10.2.2. By Workflow (Discovery, Pre-Clinical Tests, Clinical Trials)
10.2.2.1. By Discovery (Target Identification, Target Validation, Lead Discovery)
10.2.3. By Software Type (Molecular Modeling & De Novo Drug Design Software, Pharmacophore Modeling Software)
10.2.4. By Technology (Artificial Intelligence, Graphics Processing Unit, Others)
10.2.5. By Therapeutic Area (Human Immunodeficiency Virus (HIV), Infectious Diseases, Metabolic Disorders, Oncology Disorders, Others)
10.2.6. By End User (Biotechnology & Pharmaceutical Companies, Contract Research Organizations, Academic & Research Organizations, Others)
10.2.7. By Country
10.3. South America: Country Analysis
10.3.1. Brazil In Silico Drug Discovery Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Component
10.3.1.2.2. By Workflow
10.3.1.2.3. By Software Type
10.3.1.2.4. By Technology
10.3.1.2.5. By Therapeutic Area
10.3.1.2.6. By End User
10.3.2. Argentina In Silico Drug Discovery Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Component
10.3.2.2.2. By Workflow
10.3.2.2.3. By Software Type
10.3.2.2.4. By Technology
10.3.2.2.5. By Therapeutic Area
10.3.2.2.6. By End User
10.3.3. Colombia In Silico Drug Discovery Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Component
10.3.3.2.2. By Workflow
10.3.3.2.3. By Software Type
10.3.3.2.4. By Technology
10.3.3.2.5. By Therapeutic Area
10.3.3.2.6. By End User
11. Middle East and Africa In Silico Drug Discovery Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Component (Software, Software-as-a-Service, Consultancy-as-a-Service)
11.2.2. By Workflow (Discovery, Pre-Clinical Tests, Clinical Trials)
11.2.2.1. By Discovery (Target Identification, Target Validation, Lead Discovery)
11.2.3. By Software Type (Molecular Modeling & De Novo Drug Design Software, Pharmacophore Modeling Software)
11.2.4. By Technology (Artificial Intelligence, Graphics Processing Unit, Others)
11.2.5. By Therapeutic Area (Human Immunodeficiency Virus (HIV), Infectious Diseases, Metabolic Disorders, Oncology Disorders, Others)
11.2.6. By End User (Biotechnology & Pharmaceutical Companies, Contract Research Organizations, Academic & Research Organizations, Others)
11.2.7. By Country
11.3. MEA: Country Analysis
11.3.1. South Africa In Silico Drug Discovery Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Component
11.3.1.2.2. By Workflow
11.3.1.2.3. By Software Type
11.3.1.2.4. By Technology
11.3.1.2.5. By Therapeutic Area
11.3.1.2.6. By End User
11.3.2. Saudi Arabia In Silico Drug Discovery Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Component
11.3.2.2.2. By Workflow
11.3.2.2.3. By Software Type
11.3.2.2.4. By Technology
11.3.2.2.5. By Therapeutic Area
11.3.2.2.6. By End User
11.3.3. UAE In Silico Drug Discovery Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Component
11.3.3.2.2. By Workflow
11.3.3.2.3. By Software Type
11.3.3.2.4. By Technology
11.3.3.2.5. By Therapeutic Area
11.3.3.2.6. By End User
11.3.4. Turkey In Silico Drug Discovery Market Outlook
11.3.4.1. Market Size & Forecast
11.3.4.1.1. By Value
11.3.4.2. Market Share & Forecast
11.3.4.2.1. By Component
11.3.4.2.2. By Workflow
11.3.4.2.3. By Software Type
11.3.4.2.4. By Technology
11.3.4.2.5. By Therapeutic Area
11.3.4.2.6. By End User
11.3.5. Egypt In Silico Drug Discovery Market Outlook
11.3.5.1. Market Size & Forecast
11.3.5.1.1. By Value
11.3.5.2. Market Share & Forecast
11.3.5.2.1. By Component
11.3.5.2.2. By Workflow
11.3.5.2.3. By Software Type
11.3.5.2.4. By Technology
11.3.5.2.5. By Therapeutic Area
11.3.5.2.6. By End User
12. Market Dynamics
12.1. Drivers
12.2. Challenges
13. Market Trends & Developments
14. Competitive Landscape
14.1. Aragen Life Sciences Pvt. Ltd. (GVK Biosciences Pvt. Ltd.)
14.2. Curia Global, Inc. (Albany Molecular Research Inc.)
14.3. Charles River Laboratories International, Inc.
14.4. Chemical Computing Group ULC. (CCG)
14.5. Collaborative Drug Discovery Inc. (CDD)
14.6. e-therapeutics plc.
14.7. Dassault Systèmes SE
14.8. Insilico Medicine, Inc.
14.9. Numerate, Inc.
14.10. Schrödinger, Inc.
15. Strategic Recommendations

 

ページTOPに戻る


 

Summary

The global in silico drug discovery market is anticipated to observe impressive growth during the forecast period 2023-2027. The major factors include growing incidences of various diseases, rising use of cloud-based applications, and extensive development in technology, which are curbing the market's growth. Nowadays, in silico methodologies are becoming an essential part of the drug discovery process. This is primarily because of the impact on the whole drug development trajectory, identifying and discovering new potential drugs with a substantial reduction in cost and time. The other factors supporting the market's growth are the extensive research and development, prevalence of various diseases, large number of clinical trials, rising emphasis on reduction in medical errors and readmission rates, various investments, the growing number of collaborations between companies, and rise in the volume of drug discovery data.
Rising Adoption of Cloud-Based Applications
The increasing use of cloud applications is fueling the growth of the in-silico drug discovery market. Cloud computing gives access to pharmaceutical researchers to use virtually infinite computational resources, permitting them to scale up or down their computing environment. Cloud computing has not only enhanced overall productivity but also minimized the chances of clinical failure. For instance, in 2020, researchers at the University of Bristol alleged to have used cloud-based solutions to successfully interpret the structure of a potential preventive intervention called ADDomer.
Technological Advancements Support the Market
Rapid technological advancements in the field of computational biology are bolstering the growth of the in-silico drug discovery market globally. Computational techniques are quite effective in the development of novel pharmaceutical compounds. The advancement in technologies is simplifying the various steps in sequencing, due to which the results obtained are faster and more accurate. For instance, in 2021, Pfizer Inc. and Amazon Web Services (AWS) have approved to work together on developing novel cloud-based technologies that could modernize how new medications are studied, manufactured, and disseminated for clinical trials. Similarly, in 2022, Insilico Medicine and the University of Zurich collaborated to leverage Insilico's dynamic AI technology to discover new cystinosis treatments.
Increasing Investments and Collaborations
Heavy investments in drug discovery and development with rising occurrences of various diseases are propelling the growth of the market. For instance, in 2021, as per a report published by the Pharmaceutical Research and Manufacturers of America (PhRMA), biopharmaceutical companies invested more than a trillion dollars in R&D in the last ten years, including a record year in 2020, when PhRMA member industries alone invested approximately 91 billion USD. Furthermore, the increasing number of partnerships that AI start-ups have with leading research centers may offer an alternative metric. For instance, in 2019, as a part of a £33 million partnership with GSK that commenced in 2017, Exscientia delivered a lead molecule targeted at the treatment of chronic obstructive pulmonary disease.
Market Segmentation
The global in silico drug discovery market is segmented into components, workflow, software type, technology, therapeutic area, end user, and company. Based on components, the market is divided into software, software-as-a-service, and consultancy-as-a-service. Based on workflow, the market is divided into discovery, pre-clinical tests, and clinical trials. Based on the discovery, the market is further segmented into target identification, target validation, and lead discovery. Based on software type, the market is segmented into molecular modeling & de novo drug design software and pharmacophore modeling software. Based on technology, the market is segmented into artificial intelligence, graphics processing unit, and others. Based on therapeutic area, the market is segmented into human immunodeficiency virus (HIV), infectious diseases, metabolic disorders, oncology disorders, and others. Based on end users, the market is divided into biotechnology & pharmaceutical companies, contract research organizations, academic & research organizations, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to the extensive technology development in the country.
Market Players
Aragen Life Sciences Pvt. Ltd. (GVK Biosciences Pvt. Ltd.), Curia Global, Inc. (Albany Molecular Research Inc.), Charles River Laboratories International, Inc., Chemical Computing Group ULC. (CCG), Collaborative Drug Discovery Inc. (CDD), e-therapeutics plc., Dassault Systèmes SE, Insilico Medicine, Inc., Numerate, Inc., and Schrödinger, Inc. are some of the leading companies operating in the market.
Report Scope:
In this report, global in silico drug discovery market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:
• In Silico Drug Discovery Market, By Component:
o Software
o Software-as-a-Service
o Consultancy-as-a-Service
• In Silico Drug Discovery Market, By Workflow:
o Discovery
 Target Identification
 Target Validation
 Lead Discovery
o Pre-Clinical Tests
o Clinical Trials
• In Silico Drug Discovery Market, By Software Type:
o Molecular Modeling & De Novo Drug Design Software
o Pharmacophore Modeling Software
• In Silico Drug Discovery Market, By Technology:
o Artificial Intelligence
o Graphics Processing Unit
o Others
• In Silico Drug Discovery Market, By Therapeutic Area:
o Human Immunodeficiency Virus (HIV)
o Infectious Diseases
o Metabolic Disorders
o Oncology Disorders
o Others
• In Silico Drug Discovery Market, By End User:
o Biotechnology & Pharmaceutical Companies
o Contract Research Organizations
o Academic & Research Organizations
o Others
• In Silico Drug Discovery Market, By Region:
o North America
o United States
o Canada
o Mexico
o Asia-Pacific
o China
o India
o Japan
o Australia
o South Korea
o Europe & CIS
o Germany
o France
o United Kingdom
o Spain
o Italy
o South America
o Brazil
o Argentina
o Colombia
o Middle East & Africa
o South Africa
o Saudi Arabia
o UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in Global In Silico Drug Discovery Market
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
• Detailed analysis and profiling of additional market players (up to five).



ページTOPに戻る


Table of Contents

1. Product Overview
2. Research Methodology
3. Executive Summary
4. Impact of COVID-19 on Global In Silico Drug Discovery Market
5. Voice of Customer
6. Global In Silico Drug Discovery Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Component (Software, Software-as-a-Service, Consultancy-as-a-Service)
6.2.2. By Workflow (Discovery, Pre-Clinical Tests, Clinical Trials)
6.2.2.1. By Discovery (Target Identification, Target Validation, Lead Discovery)
6.2.3. By Software Type (Molecular Modeling & De Novo Drug Design Software, Pharmacophore Modeling Software)
6.2.4. By Technology (Artificial Intelligence, Graphics Processing Unit, Others)
6.2.5. By Therapeutic Area (Human Immunodeficiency Virus (HIV), Infectious Diseases, Metabolic Disorders, Oncology Disorders, Others)
6.2.6. By End User (Biotechnology & Pharmaceutical Companies, Contract Research Organizations, Academic & Research Organizations, Others)
6.2.7. By Company (2021)
6.2.8. By Region
6.3. Market Map
7. North America In Silico Drug Discovery Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Component (Software, Software-as-a-Service, Consultancy-as-a-Service)
7.2.2. By Workflow (Discovery, Pre-Clinical Tests, Clinical Trials)
7.2.2.1. By Discovery (Target Identification, Target Validation, Lead Discovery)
7.2.3. By Software Type (Molecular Modeling & De Novo Drug Design Software, Pharmacophore Modeling Software)
7.2.4. By Technology (Artificial Intelligence, Graphics Processing Unit, Others)
7.2.5. By Therapeutic Area (Human Immunodeficiency Virus (HIV), Infectious Diseases, Metabolic Disorders, Oncology Disorders, Others)
7.2.6. By End User (Biotechnology & Pharmaceutical Companies, Contract Research Organizations, Academic & Research Organizations, Others)
7.2.7. By Country
7.3. North America: Country Analysis
7.3.1. United States In Silico Drug Discovery Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Component
7.3.1.2.2. By Workflow
7.3.1.2.3. By Software Type
7.3.1.2.4. By Technology
7.3.1.2.5. By Therapeutic Area
7.3.1.2.6. By End User
7.3.2. Canada In Silico Drug Discovery Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Component
7.3.2.2.2. By Workflow
7.3.2.2.3. By Software Type
7.3.2.2.4. By Technology
7.3.2.2.5. By Therapeutic Area
7.3.2.2.6. By End User
7.3.3. Mexico In Silico Drug Discovery Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Component
7.3.3.2.2. By Workflow
7.3.3.2.3. By Software Type
7.3.3.2.4. By Technology
7.3.3.2.5. By Therapeutic Area
7.3.3.2.6. By End User
8. Europe In Silico Drug Discovery Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Component (Software, Software-as-a-Service, Consultancy-as-a-Service)
8.2.2. By Workflow (Discovery, Pre-Clinical Tests, Clinical Trials)
8.2.2.1. By Discovery (Target Identification, Target Validation, Lead Discovery)
8.2.3. By Software Type (Molecular Modeling & De Novo Drug Design Software, Pharmacophore Modeling Software)
8.2.4. By Technology (Artificial Intelligence, Graphics Processing Unit, Others)
8.2.5. By Therapeutic Area (Human Immunodeficiency Virus (HIV), Infectious Diseases, Metabolic Disorders, Oncology Disorders, Others)
8.2.6. By End User (Biotechnology & Pharmaceutical Companies, Contract Research Organizations, Academic & Research Organizations, Others)
8.2.7. By Country
8.3. Europe: Country Analysis
8.3.1. France In Silico Drug Discovery Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Component
8.3.1.2.2. By Workflow
8.3.1.2.3. By Software Type
8.3.1.2.4. By Technology
8.3.1.2.5. By Therapeutic Area
8.3.1.2.6. By End User
8.3.2. Germany In Silico Drug Discovery Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Component
8.3.2.2.2. By Workflow
8.3.2.2.3. By Software Type
8.3.2.2.4. By Technology
8.3.2.2.5. By Therapeutic Area
8.3.2.2.6. By End User
8.3.3. United Kingdom In Silico Drug Discovery Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Component
8.3.3.2.2. By Workflow
8.3.3.2.3. By Software Type
8.3.3.2.4. By Technology
8.3.3.2.5. By Therapeutic Area
8.3.3.2.6. By End User
8.3.4. Italy In Silico Drug Discovery Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Component
8.3.4.2.2. By Workflow
8.3.4.2.3. By Software Type
8.3.4.2.4. By Technology
8.3.4.2.5. By Therapeutic Area
8.3.4.2.6. By End User
8.3.5. Spain In Silico Drug Discovery Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Component
8.3.5.2.2. By Workflow
8.3.5.2.3. By Software Type
8.3.5.2.4. By Technology
8.3.5.2.5. By Therapeutic Area
8.3.5.2.6. By End User
9. Asia-Pacific In Silico Drug Discovery Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Component (Software, Software-as-a-Service, Consultancy-as-a-Service)
9.2.2. By Workflow (Discovery, Pre-Clinical Tests, Clinical Trials)
9.2.2.1. By Discovery (Target Identification, Target Validation, Lead Discovery)
9.2.3. By Software Type (Molecular Modeling & De Novo Drug Design Software, Pharmacophore Modeling Software)
9.2.4. By Technology (Artificial Intelligence, Graphics Processing Unit, Others)
9.2.5. By Therapeutic Area (Human Immunodeficiency Virus (HIV), Infectious Diseases, Metabolic Disorders, Oncology Disorders, Others)
9.2.6. By End User (Biotechnology & Pharmaceutical Companies, Contract Research Organizations, Academic & Research Organizations, Others)
9.2.7. By Country
9.3. Asia-Pacific: Country Analysis
9.3.1. China In Silico Drug Discovery Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Component
9.3.1.2.2. By Workflow
9.3.1.2.3. By Software Type
9.3.1.2.4. By Technology
9.3.1.2.5. By Therapeutic Area
9.3.1.2.6. By End User
9.3.2. India In Silico Drug Discovery Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Component
9.3.2.2.2. By Workflow
9.3.2.2.3. By Software Type
9.3.2.2.4. By Technology
9.3.2.2.5. By Therapeutic Area
9.3.2.2.6. By End User
9.3.3. Japan In Silico Drug Discovery Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Component
9.3.3.2.2. By Workflow
9.3.3.2.3. By Software Type
9.3.3.2.4. By Technology
9.3.3.2.5. By Therapeutic Area
9.3.3.2.6. By End User
9.3.4. South Korea In Silico Drug Discovery Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Component
9.3.4.2.2. By Workflow
9.3.4.2.3. By Software Type
9.3.4.2.4. By Technology
9.3.4.2.5. By Therapeutic Area
9.3.4.2.6. By End User
9.3.5. Australia In Silico Drug Discovery Market Outlook
9.3.5.1. Market Size & Forecast
9.3.5.1.1. By Value
9.3.5.2. Market Share & Forecast
9.3.5.2.1. By Component
9.3.5.2.2. By Workflow
9.3.5.2.3. By Software Type
9.3.5.2.4. By Technology
9.3.5.2.5. By Therapeutic Area
9.3.5.2.6. By End User
10. South America In Silico Drug Discovery Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Component (Software, Software-as-a-Service, Consultancy-as-a-Service)
10.2.2. By Workflow (Discovery, Pre-Clinical Tests, Clinical Trials)
10.2.2.1. By Discovery (Target Identification, Target Validation, Lead Discovery)
10.2.3. By Software Type (Molecular Modeling & De Novo Drug Design Software, Pharmacophore Modeling Software)
10.2.4. By Technology (Artificial Intelligence, Graphics Processing Unit, Others)
10.2.5. By Therapeutic Area (Human Immunodeficiency Virus (HIV), Infectious Diseases, Metabolic Disorders, Oncology Disorders, Others)
10.2.6. By End User (Biotechnology & Pharmaceutical Companies, Contract Research Organizations, Academic & Research Organizations, Others)
10.2.7. By Country
10.3. South America: Country Analysis
10.3.1. Brazil In Silico Drug Discovery Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Component
10.3.1.2.2. By Workflow
10.3.1.2.3. By Software Type
10.3.1.2.4. By Technology
10.3.1.2.5. By Therapeutic Area
10.3.1.2.6. By End User
10.3.2. Argentina In Silico Drug Discovery Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Component
10.3.2.2.2. By Workflow
10.3.2.2.3. By Software Type
10.3.2.2.4. By Technology
10.3.2.2.5. By Therapeutic Area
10.3.2.2.6. By End User
10.3.3. Colombia In Silico Drug Discovery Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Component
10.3.3.2.2. By Workflow
10.3.3.2.3. By Software Type
10.3.3.2.4. By Technology
10.3.3.2.5. By Therapeutic Area
10.3.3.2.6. By End User
11. Middle East and Africa In Silico Drug Discovery Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Component (Software, Software-as-a-Service, Consultancy-as-a-Service)
11.2.2. By Workflow (Discovery, Pre-Clinical Tests, Clinical Trials)
11.2.2.1. By Discovery (Target Identification, Target Validation, Lead Discovery)
11.2.3. By Software Type (Molecular Modeling & De Novo Drug Design Software, Pharmacophore Modeling Software)
11.2.4. By Technology (Artificial Intelligence, Graphics Processing Unit, Others)
11.2.5. By Therapeutic Area (Human Immunodeficiency Virus (HIV), Infectious Diseases, Metabolic Disorders, Oncology Disorders, Others)
11.2.6. By End User (Biotechnology & Pharmaceutical Companies, Contract Research Organizations, Academic & Research Organizations, Others)
11.2.7. By Country
11.3. MEA: Country Analysis
11.3.1. South Africa In Silico Drug Discovery Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Component
11.3.1.2.2. By Workflow
11.3.1.2.3. By Software Type
11.3.1.2.4. By Technology
11.3.1.2.5. By Therapeutic Area
11.3.1.2.6. By End User
11.3.2. Saudi Arabia In Silico Drug Discovery Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Component
11.3.2.2.2. By Workflow
11.3.2.2.3. By Software Type
11.3.2.2.4. By Technology
11.3.2.2.5. By Therapeutic Area
11.3.2.2.6. By End User
11.3.3. UAE In Silico Drug Discovery Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Component
11.3.3.2.2. By Workflow
11.3.3.2.3. By Software Type
11.3.3.2.4. By Technology
11.3.3.2.5. By Therapeutic Area
11.3.3.2.6. By End User
11.3.4. Turkey In Silico Drug Discovery Market Outlook
11.3.4.1. Market Size & Forecast
11.3.4.1.1. By Value
11.3.4.2. Market Share & Forecast
11.3.4.2.1. By Component
11.3.4.2.2. By Workflow
11.3.4.2.3. By Software Type
11.3.4.2.4. By Technology
11.3.4.2.5. By Therapeutic Area
11.3.4.2.6. By End User
11.3.5. Egypt In Silico Drug Discovery Market Outlook
11.3.5.1. Market Size & Forecast
11.3.5.1.1. By Value
11.3.5.2. Market Share & Forecast
11.3.5.2.1. By Component
11.3.5.2.2. By Workflow
11.3.5.2.3. By Software Type
11.3.5.2.4. By Technology
11.3.5.2.5. By Therapeutic Area
11.3.5.2.6. By End User
12. Market Dynamics
12.1. Drivers
12.2. Challenges
13. Market Trends & Developments
14. Competitive Landscape
14.1. Aragen Life Sciences Pvt. Ltd. (GVK Biosciences Pvt. Ltd.)
14.2. Curia Global, Inc. (Albany Molecular Research Inc.)
14.3. Charles River Laboratories International, Inc.
14.4. Chemical Computing Group ULC. (CCG)
14.5. Collaborative Drug Discovery Inc. (CDD)
14.6. e-therapeutics plc.
14.7. Dassault Systèmes SE
14.8. Insilico Medicine, Inc.
14.9. Numerate, Inc.
14.10. Schrödinger, Inc.
15. Strategic Recommendations

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(バイオ薬物)の最新刊レポート

TechSci Research 社の最新刊レポート


よくあるご質問


TechSci Research社はどのような調査会社ですか?


テックサイリサーチ(TechSci Research)は、カナダ、英国、インドに拠点を持ち、化学、IT、環境、消費財と小売、自動車、エネルギーと発電の市場など、多様な産業や地域を対象とした調査・出版活... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/07/23 10:28

157.74 円

172.13 円

206.60 円

ページTOPに戻る